“On July 14th 2020, the UK’s leading independent scientific body on drugs has launched the Drug Science Medical Psychedelics Working Group.
Drug Science provides an evidence base free from political or commercial influence, creating the foundation for sensible and effective drug laws, by delivering, reviewing and investigating scientific evidence relating to psychoactive drugs.
Drug Science believes that the future of psychedelic medicine is extremely promising, and there is potential for widespread application of psychedelic drugs within public health models. The UK is a world leader in the development of clinical psychedelic research, which is now expanding globally.
However, current UK regulations have created serious and considerable barriers to legitimate research associated with Schedule 1 regulations. While current legislation does not preclude scientific research with these drugs, it does make them significantly more difficult, time-consuming and costly to study.
With a greater understanding amongst policy makers, academics, the media and the general public, there are realistic prospects of regulatory approval, leading to the evidenced possibility that medical psychedelics can be used safely, feasibly and with the potential for lasting therapeutic benefits.
Building off the success of the Medical Cannabis Working Group, the Medical Psychedelics Working Group is a consortium of Drug Science experts, leading academics, researchers and policy specialists, supported by industry partners.”
